Cancer Monoclonal Antibodies Market: Growth Opportunities led by Amgen Inc. and Astellas Pharma Inc. - Technavio

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The cancer monoclonal antibodies market report is a comprehensive research that provides in-depth qualitative and quantitative intelligence. Technavio's analysts estimate a market share growth of USD 33.10 billion from 2020 to 2025, at a CAGR of 8.23%. Technavio has extensively analyzed 15 major vendors, including Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA. This research report aims to capture and analyze the trends, drivers, and challenges that are evolving in the market.

The report extensively covers the cancer monoclonal antibodies market segmentation by type (naked monoclonal antibodies and conjugated and bi-specific monoclonal antibodies) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Request a Free Sample Report

Cancer Monoclonal Antibodies Market - Vendors

The market is characterized largely by global vendors. These vendors are investing in technologies to develop advanced biologic therapeutics, such as monoclonal antibodies, for the treatment of various chronic diseases. The key vendors in the global cancer monoclonal antibodies market are focusing on product approvals, M&A, and product launches to gain a competitive edge in the market. 

Product Insights and News

• Amgen Inc.: The company offers BLINCYTO, which is blinatumomab, a bispecific CD19 directed CD3 T cell engager. It is indicated for the treatment of B cell precursor acute lymphoblastic leukemia and relapsed or refractory B cell precursor acute lymphoblastic leukemia. The company also offers Vectibix, which is a fully human monoclonal antibody specific to the epidermal growth factor receptor used for the treatment of wild type RAS metastatic colorectal cancer.

• Astellas Pharma Inc - The company, by working jointly with Seattle Genetics, develops and offers the Padcev drug to treat locally advanced or metastatic urothelial cancer.

• AstraZeneca Plc - The company offers IMFINZI, which is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of PD L 1 with the PD 1 and CD80 molecules used for the treatment of lung cancer and bladder cancer.

For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report.

Cancer Monoclonal Antibodies Market - Geographical Landscape

North America is estimated to account for 55% of the market's growth during the forecast period. The cancer monoclonal antibodies market in North America is mostly centered in the US. The market in this region will expand more slowly than markets in Europe and Asia. Over the course of the projection period, the expansion of the North American market for cancer monoclonal antibodies will be supported by the increased incidence of various types of cancer.

Cancer Monoclonal Antibodies Market - Market Segmentation

The naked monoclonal antibodies segment is estimated to contribute the highest market share to the global market's growth during the forecast period. Naked monoclonal antibodies are the most commonly used monoclonal antibodies. They are also known as targeted therapies. The naked monoclonal antibodies segment is expected to grow at a faster pace than other segments during the forecast period. The rapid growth of biotechnology has driven the use of naked monoclonal antibodies for cancer treatment. During the forecast period, new naked monoclonal antibodies, which are currently in clinical trials, are expected to receive approval. These factors will further drive market growth. Download a free sample report

What are the key data covered in this cancer monoclonal antibodies market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the cancer monoclonal antibodies market between 2021 and 2025
• Precise estimation of the size of the cancer monoclonal antibodies market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the cancer monoclonal antibodies market across North America, Europe, Asia, and ROW
• Thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of cancer monoclonal antibodies market vendors

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

Related Reports:

Non-melanoma Skin Cancer Market by Type and Geography - Forecast and Analysis 2022-2026: The non-melanoma skin cancer market size is projected to grow by USD 180.97 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.76%.

Anaplastic Thyroid Cancer Drugs Market by Product and Geography - Forecast and Analysis 2022-2026: The anaplastic thyroid cancer drugs market size is projected to grow by USD 230.53 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%.

Browse for Technavio "Health Care" Research Reports

Table of Contents

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 01: Parent market
• Exhibit 02: Market characteristics

• 2.2 Value chain analysis 
• Exhibit 03: Value Chain Analysis: Pharmaceuticals

3 Market Sizing

• 3.1 Market definition 
• Exhibit 04: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 05: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025
• Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
• Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 08: Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers 
• Exhibit 09: Bargaining power of buyers

• 4.3 Bargaining power of suppliers 
• Exhibit 10: Bargaining power of suppliers

• 4.4 Threat of new entrants 
• Exhibit 11: Threat of new entrants

• 4.5 Threat of substitutes 
• Exhibit 12: Threat of substitutes

• 4.6 Threat of rivalry 
• Exhibit 13: Threat of rivalry

• 4.7 Market condition 
• Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Type

• 5.1 Market segments 
• Exhibit 15: Type - Market share 2020-2025 (%)

• 5.2 Comparison by Type 
• Exhibit 16: Comparison by Type

• 5.3 Naked monoclonal antibodies - Market size and forecast 2020-2025 
• Exhibit 17: Naked monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
• Exhibit 18: Some US-FDA and EU approved naked cancer monoclonal antibodies
• Exhibit 19: Naked monoclonal antibodies - Year-over-year growth 2020-2025 (%)

• 5.4 Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025 
• Exhibit 20: Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
• Exhibit 21: Conjugated and bi-specific monoclonal antibodies - Year-over-year growth 2020-2025 (%)

• 5.5 Market opportunity by Type 
• Exhibit 22: Market opportunity by Type

6 Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 24: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison 
• Exhibit 25: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025
• Exhibit 26: North America - Market size and forecast 2020-2025 ($ million)
• Exhibit 27: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025
• Exhibit 28: Europe - Market size and forecast 2020-2025 ($ million)
• Exhibit 29: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025
• Exhibit 30: Asia - Market size and forecast 2020-2025 ($ million)
• Exhibit 31: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025
• Exhibit 32: ROW - Market size and forecast 2020-2025 ($ million)
• Exhibit 33: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries 
• Exhibit 34: Key leading countries

• 7.8 Market opportunity by geography 
• Exhibit 35: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges 
• Exhibit 36: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Vendor landscape 
• Exhibit 37: Vendor landscape

• 9.2 Landscape disruption 
• Exhibit 38: Landscape disruption
• Exhibit 39: Industry risks

• 9.3 Competitive scenario

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 40: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 41: Market positioning of vendors

• 10.3 Amgen Inc. 
• Exhibit 42: Amgen Inc. - Overview
• Exhibit 43: Amgen Inc. - Business segments
• Exhibit 44: Amgen Inc. – Key news
• Exhibit 45: Amgen Inc. - Key offerings

• 10.4 Astellas Pharma Inc. 
• Exhibit 46: Astellas Pharma Inc. - Overview
• Exhibit 47: Astellas Pharma Inc. - Product and service
• Exhibit 48: Astellas Pharma Inc. - Key offerings

• 10.5 AstraZeneca Plc 
• Exhibit 49: AstraZeneca Plc - Overview
• Exhibit 50: AstraZeneca Plc - Product and service
• Exhibit 51: AstraZeneca Plc – Key news
• Exhibit 52: AstraZeneca Plc - Key offerings

• 10.6 Bristol Myers Squibb Co.

• 10.7 F. Hoffmann La Roche Ltd. 
• Exhibit 58: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 59: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 60: F. Hoffmann La Roche Ltd. – Key news
• Exhibit 61: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 62: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Johnson and Johnson Inc. 
• Exhibit 63: Johnson and Johnson Inc. - Overview
• Exhibit 64: Johnson and Johnson Inc. - Business segments
• Exhibit 65: Johnson and Johnson Inc. – Key news
• Exhibit 66: Johnson and Johnson Inc. - Key offerings
• Exhibit 67: Johnson and Johnson Inc. - Segment focus

• 10.9 Merck and Co. Inc. 
• Exhibit 68: Merck and Co. Inc. - Overview
• Exhibit 69: Merck and Co. Inc. - Business segments
• Exhibit 70: Merck and Co. Inc. – Key news
• Exhibit 71: Merck and Co. Inc. - Key offerings
• Exhibit 72: Merck and Co. Inc. - Segment focus

• 10.10 Novartis AG 
• Exhibit 73: Novartis AG - Overview
• Exhibit 74: Novartis AG - Business segments
• Exhibit 75: Novartis AG. – Key news
• Exhibit 76: Novartis AG - Key offerings
• Exhibit 77: Novartis AG - Segment focus

• 10.11 Pfizer Inc. 
• Exhibit 78: Pfizer Inc. - Overview
• Exhibit 79: Pfizer Inc. - Business segments
• Exhibit 80: Pfizer Inc.- Key news
• Exhibit 81: Pfizer Inc. - Key offerings

• 10.12 Sanofi SA 
• Exhibit 82: Sanofi SA - Overview
• Exhibit 83: Sanofi SA - Business segments
• Exhibit 84: Sanofi SA – Key news
• Exhibit 85: Sanofi SA - Key offerings
• Exhibit 86: Sanofi SA - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$ 
• Exhibit 87: Currency conversion rates for US$

• 11.3 Research methodology 
• Exhibit 88: Research Methodology
• Exhibit 89: Validation techniques employed for market sizing
• Exhibit 90: Information sources

• 11.4 List of abbreviations 
• Exhibit 91: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

Newsroom: https://newsroom.technavio.org/news/cancer-monoclonal-antibodiesmarket

SOURCE Technavio